Search results for "FDA update"


 
Results 11 - 20 of about 98 for "FDA update".

FDA urges patients to use caution when injecting insulin with pen needles | ACP Diabetes Monthly

The agency offered new recommendations after receiving reports of patients using standard pen needles to inject insulin without removing the inner needle cover.

Alert on canagliflozin and amputations | ACP Diabetes Monthly

An ongoing clinical trial found an increase in leg and foot amputations, mostly affecting the toes, in patients treated with canagliflozin (Invokana, Invokamet), according to an FDA safety alert.

New long-acting insulin drugs approved | ACP Diabetes Monthly

Insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg 70/30) were approved by the FDA on Sept. 25.

New indication approved for empagliflozin | ACP Diabetes Monthly

Empagliflozin (Jardiance) is approved for a new indication—to reduce the risk of cardiovascular death in adults with type 2 diabetes and cardiovascular disease.

FDA approves new treatment for diabetic foot ulcers | ACP Diabetes Monthly

The approval is an expanded indication for the device, which covers the ulcer and allows skin and tissue to regenerate and heal the wound.

Hemoglobin A1c test approved for diagnosis | ACP Diabetes Monthly

The FDA recently approved the first hemoglobin A1c (HbA1c) test specifically labeled for diagnosing diabetes.

Insulin needles failing to deploy | ACP Diabetes Monthly

Several lots of the OmniPod Insulin Management System were affected by a recent field safety notification about needle mechanisms failing to deploy or demonstrating a delay in deployment.

First continuous glucose monitoring system approved to be used with other devices | ACP Diabetes Monthly

The system is the first approved to be used with other diabetes devices, such as automated insulin-dosing systems, insulin pumps, or blood glucose meters, according to the FDA.

New contraindication for aliskiren-containing medications | ACP Diabetes Monthly

Aliskiren-containing medications are contraindicated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with diabetes.

Combo of metformin and dapagliflozin approved | ACP Diabetes Monthly

A once-daily combination pill of dapagliflozin and metformin HCl extended-release (Xigduo XR) was recently approved by the FDA.

Result Page: Prev   1   2   3   4   5   6   7   8   9   10   Next